Rheumatoid Arthritis: World Drug Market 2011-2021
How will the market for rheumatoid arthritis treatments perform from 2011? Visiongain's report shows you potential revenues to 2021, discussing opportunities and prospects.
Discover rheumatoid arthritis drug revenues at total world, submarket, product and national levels. Through our research and analysis we aim to save you time and help in your decisions.
See how drugs such as Celebrex, Arcoxia, Humira, Remicade, Enbrel, MabThera and Cimzia can perform to 2021, finding potential revenues. How will competition affect the market?
Discover commercial prospects for biological and non-biological drugs for rheumatoid arthritis. Receive data you need for non-steroidal anti-inflammatory drugs (NSAIDs) and other products.
There is a strong R&D pipeline for treating inflammatory diseases. We cover NSAIDs, corticosteroids and biologics for rheumatoid arthritis. Find R&D trends.
Our report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.
Analysis with revenues, future growth rates, market shares, opinions and discussions
In our report you find revenue forecasts, growth rates, market shares, qualitative analyses (incl. SWOT), an R&D review and opinions from our survey. You receive 69 tables and charts and two research interviews (see the table of contents).
Rheumatoid Arthritis: World Drug Market 2011-2021 shows you opportunities, challenges and revenue forecasts
Our report gives you the following advantages in particular:
Order our report now to gain industry and market analysis for rheumatoid arthritis
Our report is for everybody needing industry and market analysis for rheumatoid arthritis treatments. Find trends and answers. Avoid missing out - please order our report now.
Discover rheumatoid arthritis drug revenues at total world, submarket, product and national levels. Through our research and analysis we aim to save you time and help in your decisions.
See how drugs such as Celebrex, Arcoxia, Humira, Remicade, Enbrel, MabThera and Cimzia can perform to 2021, finding potential revenues. How will competition affect the market?
Discover commercial prospects for biological and non-biological drugs for rheumatoid arthritis. Receive data you need for non-steroidal anti-inflammatory drugs (NSAIDs) and other products.
There is a strong R&D pipeline for treating inflammatory diseases. We cover NSAIDs, corticosteroids and biologics for rheumatoid arthritis. Find R&D trends.
Our report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.
Analysis with revenues, future growth rates, market shares, opinions and discussions
In our report you find revenue forecasts, growth rates, market shares, qualitative analyses (incl. SWOT), an R&D review and opinions from our survey. You receive 69 tables and charts and two research interviews (see the table of contents).
Rheumatoid Arthritis: World Drug Market 2011-2021 shows you opportunities, challenges and revenue forecasts
Our report gives you the following advantages in particular:
- Find revenue predictions to 2021 for the world rheumatoid arthritis drug market and submarkets, seeing revenue growth
- Discover revenue forecasts to 2021 for leading products, assessing market potentials
- Assess leading companies, discovering their activities and outlooks
- See revenue forecasts to 2021 for leading national markets - US, Japan, Germany, France, UK, Spain, Italy, China and India
- Review R&D for treating rheumatoid arthritis, seeing pipeline trends
- Investigate competition and opportunities influencing the industry and market
- See what will stimulate and restrain the industry and market from 2011
- View opinion from our survey, receiving full interview transcripts.
Order our report now to gain industry and market analysis for rheumatoid arthritis
Our report is for everybody needing industry and market analysis for rheumatoid arthritis treatments. Find trends and answers. Avoid missing out - please order our report now.
Contents
1. EXECUTIVE SUMMARY1.1 World Rheumatoid Arthritis Treatments Market Outlook
1.2 Aims Scope and Format of the Report
1.3 Research and Analysis Methods
1.4 Chapter Outlines
2. INTRODUCTION TO RHEUMATOID ARTHRITIS
2.1 What is Rheumatoid Arthritis?
2.2 Understanding Joints
2.3 What Causes Rheumatoid Arthritis?
2.3.1 Overactive Immune System: The Immune Response and Inflammation Process
2.3.2 Genetic Factors
2.3.3 Environmental Triggers
2.4 Diagnosis of Rheumatoid Arthritis
2.4.1 Radiographic Features of Rheumatoid Arthritis
2.4.2 Blood Tests
2.4.3 Disorders with Similar Symptoms
2.5 Disease Risk Factors
2.6 Managing Rheumatoid Arthritis
2.6.1 Main Treatments Offered
2.6.2 Other Treatments Offered
2.6.3 Diet and Complementary Therapies
2.6.4 Surgical Options
2.6.5 Monitoring Disease Progression
2.7 Economic Costs of Rheumatoid Arthritis
2.8 World Prevalence of Rheumatoid Arthritis
2.9 Uncertainty on the Incidence of Rheumatoid Arthritis
3. TREATMENTS FOR RHEUMATOID ARTHRITIS
3.1 What Drugs Are Used to Treat RA?
3.2 Pain Relieving Drugs
3.2.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
3.2.2 Side-Effects of NSAIDs
3.3 Corticosteroids
3.4 Disease Modifying Anti-Rheumatic Drugs (DMARDs)
3.4.1 Methotrexate
3.4.2 Biologics
3.4.3 Hydroxychloroquine and Sulfasalazine
3.4.4 Minocycline
3.4.5 Leflunomide
3.4.6 Cyclosporine
3.4.7 Azathioprine
3.5 Biologics for Rheumatoid Arthritis Treatment
3.5.1 What is Tumour Necrosis Factor?
3.5.2 Side-Effects of Biologics
3.5.3 Combining Biologics with DMARDs
3.6 Key Treatments in the RA Drug Market
4. THE GLOBAL RHEUMATOID ARTHRITIS DRUG MARKET, 2011-2021
4.1 The Global Rheumatoid Arthritis Market, 2011-2021
4.2 Non-Biologics for RA
4.2.1 NSAIDs: Market Forecast, 2011-2021
4.2.2 Other Non-Biologics for RA: Market Forecast, 2011-2021
4.3 Biologics for RA: Market Forecast 2011-2021
4.3.1True Contribution of Biologics in the RA Market
4.4 Summary of the Market
5. MAIN DRUGS IN THE RHEUMATOID ARTHRITIS MARKET, 2011-2021
5.1 Non Steroidal Anti-Inflammatory Drugs (NSAIDs)
5.1.1 Celebrex (Pfizer): Market Forecast, 2011-2021
5.1.1.1 Development of Celebrex
5.1.2 Arcoxia (Merck and Co.): Market Forecast, 2011-2021
5.1.2.1 Development of Arcoxia
5.2 Biologics for RA Treatments
5.2.1 Humira (Abbott Laboratories): Market Forecast, 2011-2021
5.2.1.1 Long Term Prospects for Humira
5.2.2 Remicade (Johnson and Johnson): Market Forecast, 2011-2021
5.2.2.1 Long Term Prospects for Remicade
5.2.3 Enbrel (Amgen; Pfizer; Takeda): Market Forecast, 2011-2021
5.2.3.1 Amgen Continues to Benefit from Enbrel Sales
5.2.3.2 Enbrel Sales Will Show an Initial Increase
5.2.3.3 Study Eases Fears of TNF Blocker Cancer Risk
5.2.3.4 New Enbrel Delivery System
5.2.3.5 Sales of Enbrel Will Eventually Decline
5.2.3.6 Enbrel Faces Competition from Several Other Biotech Drugs
5.2.4 MabThera (Rituxan in the US - Roche; Biogen Idec): Market Forecast, 2011-2021
5.2.4.1MabThera: Leading Biologic for RA
5.2.5 Orencia (Bristol-Myers Squibb): Market Forecast, 2011-2021
5.2.5.1 Orencia: New Biologic for RA
5.2.6 Actemra (Roche): Market Forecast, 2011-2021
5.2.6.1 Actemra Will Achieve Growth
5.2.7 Cimzia (UCB): Market Forecast, 2011-2021
5.2.7.1 Cimzia: Forecast and Analysis, 2011-2021
5.2.8 Kineret (Biovitrium): Future Prospects
5.2.9 Simponi (Johnson and Johnson): Future Prospects
6. R&D PIPELINE FOR RHEUMATOID ARTHRITIS DRUGS, 2011
6.1 R&D Pipeline: NSAIDs for Rheumatoid Arthritis, 2011
6.1.1 Famotidine + Ibuprofen (Horizon)
6.1.2 Ibuprofen-PC (PLx Pharma)
6.1.3 Apricoxib (Tragara; Daiichi Sankyo)
6.1.4 CEP 33222 (Cephalon; Acusphere)
6.2 R&D Pipeline: Corticosteroids for Rheumatoid Arthritis, 2011
6.2.1 Lodotra (Horizon; SkyePharma)
6.3 R&D Pipeline: Biologics to Treat Rheumatoid Arthritis, 2011
6.3.1 Denosumab (Amgen)
6.3.2 Fostamatinib (AstraZeneca)
6.3.3 Tofacitinib (Pfizer)
6.3.4 Ofatumumab (Genmab; GSK)
6.3.5 Masitinib (AB Science)
6.3.6 Belimumab (GSK; Human Genome Sciences)
6.3.7 Canakinumab (Novartis)
6.3.8 Baminercept Alfa (Biogen Idec)
6.3.9 Ocrelizumab (Roche)
6.3.10 Sarilumab (Regeneron; Sanofi)
6.3.11 dnaJP1 (Adeona)
6.3.12 T-5224 (Roche; Toyoma Chemicals)
6.3.13 Anti- BAFF Monoclonal Antibody (Eli Lilly)
6.3.14 Olokizumab (UCB)
6.3.15 Anti-IL-17 Monoclonal Antibody (Eli Lilly)
6.3.16 JAK1/JAK2 Inhibitor (Eli Lilly)
6.3.17 Sirukumab (Johnson and Johnson)
6.3.18 INCB018424 (Incyte Corporation)
6.3.19 ALD 518 (Bristol Myers Squibb; Alder Biopharmaceuticals)
6.3.20 GSK3152314A (GlaxoSmithKline)
6.3.21 RPI-MN (ReceptoPharm)
6.3.22 MT203 (Nycomed)
7. LEADING NATIONAL MARKETS FOR RHEUMATOID ARTHRITIS TREATMENTS, 2011-2021
7.1 Leading National Markets for Rheumatoid Arthritis, 2010-2021
7.2 The US Rheumatoid Arthritis Market, 2011-2021
7.3 The Japanese Rheumatoid Arthritis Market, 2011-2021
7.4 The Leading European Markets for Rheumatoid Arthritis Treatments, 2011-2021
7.5 Rheumatoid Arthritis Drug Market in Emerging Economies, 2011-2021
7.5.1 The Chinese Rheumatoid Arthritis Market, 2011-2021
7.5.2 The Indian Rheumatoid Arthritis Market, 2011-2021
7.6 Rheumatoid Arthritis Treatments in the Rest of the World, 2011-2021
7.7 Summary of National Market Forecasts
8. LEADING COMPANIES IN THE RHEUMATOID ARTHRITIS DRUG MARKET, 2011
8.1 Introduction
8.2 Roche
8.3 Abbott Laboratories
8.4 Amgen
8.5 Johnson & Johnson
8.6 Biogen Idec
9. DRIVERS AND RESTRAINTS IN THE RHEUMATOID ARTHRITIS DRUG MARKET
9.1 SWOT Analysis of the RA Drug Market
9.2 Commercial Drivers in the RA Drug Market
9.2.1 The Biological Drug Market for RA is Well-Established
9.2.2 New Product Development Will Drive the RA Market
9.2.3 Rising Prevalence of RA Will Enhance Market Growth
9.2.4 Small Molecules Will Have a Positive Impact on RA Treatments
9.2.5 Revised Treatment Classification Criteria Will Make Diagnosis Easier
9.3 Commercial Restraints in the RA Drug Market
9.3.1 Biological Drugs - Too Costly in Most Countries?
9.3.2 The Biological Drug Industry - Insufficiently Dynamic?
9.3.3 Unmet Clinical Needs in Rheumatoid Arthritis Treatment Will Slow Growth
9.3.4 Biosimilar Competition May Restrain the RA Market for Biologics
9.3.5 Side-Effects and Costly Treatments
9.3.6 Inadequate Reimbursement for Biologics Will Hamper RA Market Growth
9.4 Concluding Remarks
10. RESEARCH INTERVIEWS
10.1 Interview 1: Dr Yusuf Yazici, MD, Assistant Professor, Department of Medicine-Rheumatology and Hospital for Joint Diseases and Medicine, New York University
10.1.1 Opinion on the Key Unmet Needs for RA Treatments
10.1.2 Opinions on Current Treatments
10.1.3 Views on Abatacept: New Biologic for RA
10.1.4 Key Challenges: Development and Uptake of Abatacept
10.1.5 Views on Cimzia
10.1.6 Treatments in the R&D Pipeline
10.1.7 Views on the Prevalence of RA
10.2 Interview 2: A Professor Working in Rheumatology
10.2.1 Views on the Prevalence of RA
10.2.2 Views on Anti-TNF Therapies for RA
10.2.3 Opinion on Biosimilars
10.2.4 Key Challenges in the Market
10.2.5 Key Treatment Goals
11. CONCLUSIONS
11.1 The RA Market - Revenue Growth
11.2 Non-Biologic Treatments
11.3 Biologic Treatments
11.4 Improvements Needed in RA Treatments
11.5 Future Rheumatoid Arthritis Treatments: R&D Efforts Promising
11.6 The RA Treatments Sector: Looking into the Future Confidently
LIST OF TABLES
Table 2.1 Diseases with Symptoms Similar to RA, 2011
Table 3.1 Main Treatments for RA, 2011
Table 3.2 Revenues ($bn) for Main Biologics (All Inflammatory Indications), 2010
Table 4.1 The Global RA Drug Market Forecast ($bn), 2010-2021
Table 4.2 Total NSAIDs Market for RA Treatments ($bn), 2010-2021
Table 4.3 Other Non-Biologics Market for RA Treatments ($bn), 2010-2021
Table 4.4 Total Revenue for Main Biologics for All Inflammatory Conditions: Market Forecast ($bn), 2010-2021
Table 4.5 Estimated Contribution by Biologics for RA: Market Forecast ($bn), 2010-2021
Table 4.6 RA Treatments: Forecasts for Submarkets ($bn), 2010-2021
Table 4.7 World Rheumatoid Arthritis Treatments by Submarket ($bn), 2010, 2015 and 2021
Table 5.1 World Celebrex Revenue Forecast ($bn), 2010-2021
Table 5.2 World Arcoxia Revenue Forecast ($bn), 2010-2021
Table 5.3 NSAID Market Forecasts for RA Treatment ($bn), 2010-2021
Table 5.4 World Humira Revenue Forecast ($bn), 2010-2021
Table 5.5 World Remicade Revenue Forecast ($bn), 2010-2021
Table 5.6 World Enbrel Revenue Forecast ($bn), 2010-2021
Table 5.7 World MabThera Revenue Forecast ($bn), 2010-2021
Table 5.8 World Orencia Revenue Forecast ($bn), 2010-2021
Table 5.9 World Actemra Revenue Forecast ($bn), 2010-2021
Table 5.10 World Cimzia Revenue Forecast ($bn), 2010-2021
Table 5.11 Biologics: Revenue Forecasts ($bn), 2010-2021
Table 6.1 R&D Pipeline: NSAIDs and Painkillers, 2011
Table 6.2 R&D Pipeline: Corticosteroids, 2011
Table 6.3 R&D Pipeline: Biologics, 2011
Table 7.1 Leading National Revenues ($bn) and Market Shares (%) for RA in 2010, 2015 & 2021
Table 7.2 US RA Treatments Market Forecast ($bn), 2010-2021
Table 7.3 Japanese RA Treatments Market Forecast ($bn), 2010-2021
Table 7.4 EU5 Countries: RA Treatment Market Forecasts ($bn), 2010-2021
Table 7.5 Emerging Economies - China and India: RA Treatment Market Forecasts ($bn), 2010-2021
Table 7.6 RA Market in The Rest of The World ($bn), 2010-2021
Table 7.7 Leading National Markets for RA Treatments ($bn), 2010-2021
Table 8.1 Revenues ($bn) and Market Shares (%) of Leading Organisations for Biologics, 2010
Table 8.2 Roche: Revenues ($bn) for Key Biologics, 2010
Table 8.3 Abbott Laboratories: Revenue ($bn) for Key Biologic, 2010
Table 8.4 Amgen: Revenue ($bn) for Key Biologic, 2010
Table 8.5 Johnson and Johnson: Revenues ($bn) for Key Biologics, 2010
Table 8.6 Biogen Idec: Revenue ($bn) for Key Biologic, 2010
Table 9.1 SWOT Analysis of the Rheumatoid Arthritis Drug Market, 2011-2021
LIST OF FIGURES
Figure 4.1 The Global RA Drug Market Forecast ($bn), 2010-2021
Figure 4.2 Total NSAIDs Market for RA Treatments ($bn), 2010-2021
Figure 4.3 Other Non-Biologics Market for RA Treatments ($bn), 2010-2021
Figure 4.4 Estimated Contribution by Biologics for RA: Market Forecast ($bn), 2010-2021
Figure 4.5 World RA Treatments: Market Shares (%) by Sub Market, 2010
Figure 4.6 World RA Treatments: Market Shares (%) by Sub Market, 2015
Figure 4.7 World RA Treatments: Market Shares (%) by Sub Market, 2021
Figure 5.1 World Celebrex Revenue Forecast ($bn), 2010-2021
Figure 5.2 World Arcoxia Revenue Forecast ($bn), 2010-2021
Figure 5.3 World Humira Revenue Forecast ($bn), 2010-2021
Figure 5.4 World Remicade Revenue Forecast ($bn), 2010-2021
Figure 5.5 World Enbrel Revenue Forecast ($bn), 2010-2021
Figure 5.6 World MabThera Revenue Forecast ($bn), 2010-2021
Figure 5.7 World Orencia Revenue Forecast ($bn), 2010-2021
Figure 5.8 World Actemra Revenue Forecast ($bn), 2010-2021
Figure 5.9 World Cimzia Revenue Forecast ($bn), 2010-2021
Figure 7.1 Leading National Market Shares (%) for RA, 2010
Figure 7.2 Leading National Market Shares (%) for RA, 2015
Figure 7.3 Leading National Market Shares (%) for RA, 2021
Figure 7.4 US RA Treatments Market Forecast ($bn), 2010-2021
Figure 7.5 Japanese RA Treatments Market Forecast ($bn), 2010-2021
Figure 7.6 US and Japanese RA Treatment Market Forecasts ($bn), 2010-2021
Figure 7.7 EU5 Countries: RA Treatment Market Forecasts ($bn), 2010-2021
Figure 7.8 Emerging Economies - China and India: RA Treatments Market Forecast ($bn), 2010-2021
Figure 7.9 RA Market in the Rest of The World ($bn), 2010-2021
Figure 8.1 Market Shares (%) of Leading Organisations for Biologics Contributing Towards RA Treatments, 2010
Figure 8.2 Roche: Sales Shares (%) for Key Biologics, 2010
Figure 8.3 Abbott Laboratories: Sales Share (%) for Key Biologic, 2010
Figure 8.4 Amgen: Sales Share (%) for Key Biologic, 2010
Figure 8.5 Johnson and Johnson: Sales Shares (%) for Key Biologics, 2010
Figure 8.6 Biogen Idec: Sales Share (%) for Key Biologic, 2010
COMPANIES LISTED
AB Science
Abbott Laboratories
Acusphere
Adeona Pharmaceuticals
Alder Biopharmaceuticals
American College of Rheumatology
Amgen
Arthritis Foundation of America
Astellas
AstraZeneca
Biogen Idec
Biovitrum
Bristol-Myers Squibb (BMS)
Celgene
Centocor Ortho Biotech
Cephalon
Chugai
Daiichi Sankyo
Eisai
Eli Lilly
European Commission
European League Against Rheumatism (EULAR)
European Medicines Agency (EMA/EMEA)
Food and Drug Administration (US FDA)
GE Healthcare
Genentech (owned by Roche)
Genmab
Genzyme (owned by Sanofi)
Gilead Sciences
GlaxoSmithKline (GSK)
Horizon Pharma
Human Genome Sciences
Imperial College London
Incyte Corporation
Japanese Ministry of Health, Labour and Welfare
Johnson & Johnson
Kitasato University
Kobe University
mAb Discovery
Medicare
Merck & Co.
Mitsubishi Tanabe Pharma
National Health Service (UK NHS)
National Rheumatoid Arthritis Society (NRAS)
New York University
Novartis
Nycomed
Otsuka Pharmaceutical
Pfizer
PharmaNet Development Group
PLx Pharma
Radient Pharmaceuticals
ReceptoPharm
Regeneron
Rigel Pharmaceuticals
Roche
Rules-Based Medicine
Sanofi
Schering-Plough (now part of Merck and Co.)
SkyePharma
Teva
Takeda
Toyoma Chemical
Tragara Pharmaceuticals
UCB
World Health Organization (WHO)
Wyeth (now part of Pfizer)
Zenyaku Kogyo Skip to top